You are here

Article info

Article menu
Basic tumor immunology
Original research
Prophylactic IL-23 blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy

Authors

  • Mingyi Ju Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, ChinaLiaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, China PubMed articlesGoogle scholar articles
  • Jiaojiao Zhang Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, ChinaLiaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, China PubMed articlesGoogle scholar articles
  • Zhuoyuan Deng Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, ChinaLiaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, China PubMed articlesGoogle scholar articles
  • Minjie Wei Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, ChinaLiaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, ChinaLiaoning Medical Diagnosis and Treatment Center, Shenyang, China PubMed articlesGoogle scholar articles
  • Lianghua Ma Department of Radiation Oncology, The First Affiliated Hospital of China Medical University, Shenyang, China PubMed articlesGoogle scholar articles
  • Ting Chen Department of Orthopedics, Shengjing Hospital of China Medical University, Shenyang, China PubMed articlesGoogle scholar articles
  • Lin Zhao Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, ChinaLiaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, China PubMed articlesGoogle scholar articles

Citation

Ju M, Zhang J, Deng Z, et al
Prophylactic IL-23 blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
Journal for ImmunoTherapy of Cancer 2024;12:e009345. doi: 10.1136/jitc-2024-009345
Online issue publication 
July 31, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.